Suchen
Organon & Co
OGNZur Watchlist hinzufügen
13.556USD
+0.006+0.04%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.52BMarktkapitalisierung
14.36KGV TTM
mehr Informationen über Organon & Co Unternehmen
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
Organon & Co Informationen
BörsenkürzelOGN
Name des UnternehmensOrganon & Co
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)
Anzahl der mitarbeiter10000
WertpapierartOrdinary Share
GeschäftsjahresendeMay 14
Addresse30 Hudson Street
StadtJERSEY CITY
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl07302
Telefon15514306000
Websitehttps://www.organon.com/
BörsenkürzelOGN
IPO-datumMay 14, 2021
CEOMorrissey (Joseph T)
Führungskräfte von Organon & Co
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Independent Director
Independent Director
2.00
--
Dr. Juan Camilo Arjona Ferreira
Dr. Juan Camilo Arjona Ferreira
Executive Vice President, Head of Research and Development and Chief Medical Officer
Executive Vice President, Head of Research and Development and Chief Medical Officer
--
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Robert A. (Bob) Essner
Mr. Robert A. (Bob) Essner
Lead Independent Director
Lead Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Matthew M. (Matt) Walsh
Mr. Matthew M. (Matt) Walsh
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.75K
--
Ms. Rachel A. Stahler
Ms. Rachel A. Stahler
Executive Vice President, Chief Digital and Growth Officer
Executive Vice President, Chief Digital and Growth Officer
116.52K
+0.36%
Mr. Aaron Falcione
Mr. Aaron Falcione
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
101.67K
+4.83%
Mr. Kirke Weaver
Mr. Kirke Weaver
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
92.70K
+0.06%
Mr. Vittorio Nisita
Mr. Vittorio Nisita
Executive Vice President, Head of Enterprise Services & Solutions
Executive Vice President, Head of Enterprise Services & Solutions
70.86K
+5.78%
Ms. Rochelle B. (Shelly) Lazarus
Ms. Rochelle B. (Shelly) Lazarus
Independent Director
Independent Director
633.00
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Organon & Co?
Die fünf größten Anteilseigner von Organon & Co sind: Mr. Matthew M. (Matt) Walsh
Wie viele Institutionen halten Anteile an Organon & Co (OGN)?
Mit Stand vom 2026Q1 halten 1398 Institutionen Anteile an Organon & Co, mit einem Gesamtmarktwert von etwa 239.27M, was 91.12% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -3985201.00 gestiegen.
Was ist die größte Einnahmequelle von Organon & Co?
Am 2026Q1 erzielte das Geschäft mit Women’s Health für Organon & Co den höchsten Umsatz in Höhe von 1.75B, was 28.19% des Gesamtumsatzes entspricht.